drugset
drugset / Trial / NCT04701216

A Trial of SHR8735 in Healthy Subjects

NCT04701216 ↗

Phase 1 Completed 48 enrolled Atridia Pty Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a phase 1 open-label study.

Timeline

Start
2021-02-11
Primary completion
2021-07-15
Completion
2021-07-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Hetrombopag Small molecule — Oral

Indications

No indication recorded.